-

Equity Alert: Rosen, a Globally Recognized Firm, Announces Investigation of Securities Claims Against Apyx Medical Corporation – APYX

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) resulting from allegations that Apyx may have issued materially misleading business information to the investing public.

On March 16, 2020, Apyx announced that its financial statements for the twelve months ended December, 31 2018 and the quarterly statements for the three and nine months ended September 30, 2018 and three months ended March 31, 2019 could no longer be relied upon and would need to be restated. On this news, Apyx’s securities fell $0.23 per share, or over 5%, to close at $4.36 per share on March 17, 2020.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Apyx investors. If you purchased shares of Apyx please visit the firm’s website at http://www.rosenlegal.com/cases-register-1817.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. hundreds

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Rosen Law Firm

NASDAQ:APYX

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Social Media Profiles
More News From Rosen Law Firm

Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025. Inovio describes itself as a “biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”).” For more information, su...

Rosen Law Firm Urges Masonite International Corporation (NYSE: DOOR) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of sellers of common stock of Masonite International Corporation (NYSE: DOOR) between June 5, 2023 and February 8, 2024. Masonite describes itself as a “leading global designer, manufacturer, marketer, and distributor of interior and exterior doors and door solutions for the residential and non-residential building construction markets’ new construction and repair, renovation...

Rosen Law Firm Encourages Kyndryl Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – KD

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kyndryl Holdings, Inc. (NYSE: KD) resulting from allegations that Kyndryl may have issued materially misleading business information to the investing public. So What: If you purchased Kyndryl securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement....
Back to Newsroom